Results 51 to 60 of about 12,265 (153)

Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context

BMC Ophthalmology, 2018
Background To compare anti-VEGF treatments for macular disease in terms of costs and clinical outcomes. Methods We identified patients suffering from macular disease and treated either with aflibercept, ranibizumab or both at the largest public eye ...
Martin K. Schmid, Oliver Reich, Eva Blozik, Livia Faes, Nicolas S. Bodmer, Silvan Locher, Michael A. Thiel, Roland Rapold, Maximilian Kuhn, Lucas M. Bachmann   +9 more
doaj   +1 more source

Early high‐dose aflibercept 8 mg clinical outcomes in wet age‐related macular degeneration patients resistant to aflibercept 2 mg or faricimab

Acta Ophthalmologica, EarlyView.
Pinja Sutinen, Idan Hecht, Raimo Tuuminen   +2 more
wiley   +1 more source

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1476-1484, June 2026.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono, Martin K. H. Ho, Joanna Yang, Tonya Campbell, William Wynne, Dana Shearer, Lene Andersen, Eric Majer, Shaleesa Ledlie, Mina Tadrous, Tara Gomes   +10 more
wiley   +1 more source

Smart Polymer‐Based Drug Delivery Systems for Managing Infective Conjunctivitis: Advances and Future Prospects

Nano Select, Volume 7, Issue 6, June 2026.
The introduction covers the background and significance of conjunctivitis. It continues with a review of etiology, epidemiology, and clinical manifestations. Diagnostic methods are described, followed by discussions on pathophysiology and classification. Current treatment strategies, preventive measures, and therapeutic challenges are analyzed.
Xia Linkang, Marwan Abdelmahmoud Abdelkarim Maki, Saad Tayyab, Sachin Thakur, Pankaj Kumar, Ritu Karwasra, Mahesh Harihar Behare, Nitin Sharma, Wan Hamirul Bahrin Wan Kamal, Oganeswary Kobi, Kushagra Khanna, Mogana Rajagopal   +11 more
wiley   +1 more source

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema

Clinical Interventions in Aging, 2013
Angie HC Fong,1 Timothy YY Lai1,2 1Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong Kong; 22010 Retina and Macula Centre, Tsimshatsui, Kowloon, Hong Kong Abstract: Neovascular ...
Fong AH, Lai TY
doaj  

Comparison of the Syringe Preparation Time for Ranibizumab Prefilled Syringe versus Bevacizumab, Ranibizumab, and Aflibercept Vials

Archives of Basic and Clinical Research
Objective: To compare the syringe preparation time for ranibizumab prefilled syringe versus bevacizumab, ranibizumab, and aflibercept vials in routine retinal practice. Methods: The study was conducted retrospectively between July 2019 and February 2021
Ahmet Mehmet Somuncu, Adem Uğurlu, Nurdan Gamze Taşlı, Yücel Karakurt, İbrahim Çiçek   +4 more
doaj   +1 more source

Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective

ClinicoEconomics and Outcomes Research, 2015
Stephane A Régnier,1 William Malcolm,2 Jennifer Haig,3 Weiguang Xue41Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharmaceuticals UK Ltd, Frimley Business Park, UK; 3Optum, Burlington, ON, Canada; 4Optum, Uxbridge, UKBackground: Ranibizumab ...
Régnier SA, Malcolm W, Haig J, Xue W   +3 more
doaj  

The efficacy of ranibizumab treatment in clinical practice in patients with the wet form of age-related macular degeneration. The results of the Czech National Registry

Biomedical Papers, 2015
Aims: The aim of this communication was to evaluate ranibizumab in the treatment of wet age-related macular degeneration. Methods: Anonymised data on treatment efficacy and safety were consecutively entered into the Czech national database.
Oldrich Chrapek, Jiri Jarkovsky, Jan Studnicka, Martin Sin, Petr Kolar, Barbora Jirkova, Ladislav Dusek, Sarka Pitrova, Jiri Rehak   +8 more
doaj   +1 more source

Switching to Faricimab or High‐Dose Aflibercept for Neovascular AMD in High‐Demand Patients: Impact on Injection Interval in a Real‐World Cohort

Clinical &Experimental Ophthalmology, Volume 54, Issue 5, Page 724-726, July 2026.
Zachary George Angus, Yin‐Zhi Lee, Sukhpal Singh Sandhu, Robyn Troutbeck, Jonathan Yeoh, Daniel Chiu, Manishka Jayasundera, Jaesser Tan, Sanjeewa Wickremasinghe   +8 more
wiley   +1 more source

Combination of ranibizumab with photodynamic therapy vs ranibizumab monotherapy in the treatment of age-related macular degeneration:a systematic review and meta-analysis of randomized controlled trials

International Journal of Ophthalmology, 2014
AIM:To compare the efficacy and safety of combination of ranibizumab with photodynamic therapy (PDT) vs ranibizumab monotherapy in the treatment of age-related macular degeneration (AMD).METHODS:The Cochrane Central Register of Controlled Trials (CENTRAL)
Jun-Kang Si, Kai Tang, Hong-Sheng Bi, Da-Dong Guo, Jun-Guo Guo, Yu-Xiang Du, Yan Cui, Xue-Mei Pan, Ying Wen, Xing-Rong Wang   +9 more
doaj   +1 more source